All subjects will take SAR245409 twice daily. All subjects will receive SAR245409 as long as there is clinical benefit.
Combination therapy with SAR245409 and either bendamustine or rituximab as doublet therapy, or with bendamustine and rituximab as triplet therapy, will be administered over a 28 day cycle.
Subjects receiving the doublet containing rituximab will receive rituximab for 4 - 8 weeks.
Subjects with iNHL or MCL receiving bendamustine either as a doublet or triplet therapy will receive a maximum of 8 cycles of therapy. Subjects CLL receiving bendamustine either as a doublet or triplet therapy will receive a maximum of 6 cycles of therapy.